WJA
ABBV icon

Williams Jones & Associates’s AbbVie ABBV Stock Holding History

Williams Jones & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$3.81M Sell
52,373
-1,564
-3% -$123K 0.08% 125
2019
Q1 		$4.35M Sell
53,937
-313
-0.6% -$25.6K 0.1% 119
2018
Q4 		$5M Buy
54,250
+1,508
+3% +$133K 0.14% 103
2018
Q3 		$4.99M Sell
52,742
-706
-1% -$67K 0.1% 129
2018
Q2 		$4.95M Sell
53,448
-1,183
-2% -$116K 0.11% 126
2018
Q1 		$5.17M Sell
54,631
-731
-1% -$80.3K 0.12% 118
2017
Q4 		$5.35M Buy
55,362
+198
+0.4% +$18.7K 0.12% 118
2017
Q3 		$4.9M Sell
55,164
-978
-2% -$74.4K 0.12% 121
2017
Q2 		$4.07M Sell
56,142
-4,623
-8% -$311K 0.1% 134
2017
Q1 		$3.96M Sell
60,765
-1,163
-2% -$73.1K 0.1% 139
2016
Q4 		$3.88M Buy
61,928
+11,883
+24% +$725K 0.11% 136
2016
Q3 		$3.16M Sell
50,045
-10,350
-17% -$670K 0.09% 137
2016
Q2 		$3.74M Buy
60,395
+8,375
+16% +$510K 0.12% 127
2016
Q1 		$2.97M Sell
52,020
-3,661
-7% -$204K 0.14% 107
2015
Q4 		$3.3M Sell
55,681
-130,387
-70% -$7.51M 0.15% 104
2015
Q3 		$10.1M Buy
186,068
+2,425
+1% +$158K 0.46% 60
2015
Q2 		$12.3M Buy
183,643
+1,291
+0.7% +$84.3K 0.47% 58
2015
Q1 		$10.7M Sell
182,352
-26,049
-12% -$1.57M 0.43% 71
2014
Q4 		$13.6M Buy
208,401
+148,061
+245% +$9.33M 0.56% 51
2014
Q3 		$3.48M Buy
60,340
+865
+1% +$48K 0.16% 105
2014
Q2 		$3.36M Sell
59,475
-300,617
-83% -$15.8M 0.15% 108
2014
Q1 		$18.5M Buy
360,092
+305,124
+555% +$15.4M 0.37% 67
2013
Q4 		$2.9M Sell
54,968
-2,685
-5% -$132K 0.14% 102
2013
Q3 		$2.58M Sell
57,653
-52,920
-48% -$2.35M 0.13% 107
2013
Q2 		$4.57M Buy
+110,573
New +$4.84M 0.23% 98

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Williams Jones & Associates's ABBV Position: Q2 2019 in Review

Williams Jones & Associates reduced its AbbVie (ABBV) stake by 2.9% in Q2 2019, selling an estimated $123K and leaving 52,373 shares worth $3.81M. The position accounts for 0.08% of the portfolio, ranked #125.

Williams Jones & Associates first reported a position in ABBV in Q2 2013 and has held it in 25 quarters since. The position peaked at $18.5M in Q1 2014. 2,021 funds tracked by Wall St. Rank hold ABBV as of Q2 2019.

  • Williams Jones & Associates held 52,373 shares of AbbVie worth $3.81M as of Q2 2019.
  • Williams Jones & Associates sold 1,564 AbbVie shares in Q2 2019, an estimated $123K.
  • AbbVie made up 0.08% of Williams Jones & Associates's portfolio in Q2 2019, its #125 holding.
  • Williams Jones & Associates first reported a position in AbbVie in Q2 2013 and has held it in 25 quarters since.
  • Williams Jones & Associates's AbbVie position peaked at $18.5M in Q1 2014.
  • 2,021 funds tracked by Wall St. Rank held AbbVie as of Q2 2019.

Based on Williams Jones & Associates's 13F filing for Q2 2019, filed 14 Aug 2019.